Summary of Recommendations

Document Overview

Design and created by Guideline Central in participation with the College of American Pathologists.

Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas

College of American Pathologists

Publication Date: Feb 16, 2022

Page Last Updated: May 5, 2026

Interpretation of Recommendations

Decision Maker	Strong Recommendation	Conditional Recommendation
Patients	Most people in your situation would want the recommended course of action, and only a small proportion would not.	The majority of people in your situation would want the recommended course of action, but many would not.
Physicians	Most patients should receive the recommended course of action.	Be prepared to help patients to make a decision that is consistent with their own values.
Policy Makers	The recommendation can be adopted as a policy in most situations.	Substantial debate and involvement of stakeholders are necessary.

Document Overview

Document Title: Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas

Authoring Society: College of American Pathologists

Endorsing Society: Association for Molecular Pathology

Document Publication Date: Feb 16, 2022

Page Last Reviewed/Updated: May 5, 2026

Document Type: Guideline

Country of Publication: United States

Full Text Freely Available: Yes

Full Text Guideline: aplm.kglmeridian.com/view/journals/arpa/146/5/article-p547.xml

Source Citation: Brat DJ, Aldape K, Bridge JA, Canoll P, Colman H, Hameed MR, Harris BT, Hattab EM, Huse JT, Jenkins RB, Lopez-Terrada DH, McDonald WC, Rodriguez FJ, Souter LH, Colasacco C, Thomas NE, Yount MH, van den Bent MJ, Perry A. Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas. Arch Pathol Lab Med. 2022 Feb 17. doi: 10.5858/arpa.2021-0295-CP. Epub ahead of print. PMID: 35175291.

Supplemental Implementation Resources

Document Scope, Criteria, and Use Cases

Document Objectives: To develop evidence-based recommendations for informing molecular biomarker testing for pediatric and adult patients with DGs and provide guidance for appropriate laboratory test and biomarker selection for optimal diagnosis, risk stratification, and prediction.

Scope: Assessment and Screening, Diagnosis

Diseases/Conditions (MeSH)

D005910 - Glioma

D015415 - Biomarkers

D014408 - Biomarkers, Tumor

D005910 - Glioma

D015415 - Biomarkers

D014408 - Biomarkers, Tumor

Keywords: Gliomas, Molecular Biomarkers, biomarkers, brain cancer

Inclusion Criteria: Male, Female, Adolescent, Adult, Child, Older Adult

Health Care Settings: Ambulatory, Hospital, Laboratory Services, Outpatient

Intended Users: Nurse, Nurse Practitioner, Physician, Physician Assistant

Recommendation Development Processes & Methodology

Supplemental Methodology Resources: Data Supplement Methodology Supplement

Number of Source Documents: 196

Literature Search Start Date: Sunday, November 12, 2017

Literature Search End Date: Thursday, July 23, 2020

Includes peer/external review process?: Yes

Includes public comment process?: Yes

Methodologist involvement?: Yes

Patient involvement?: No

Includes multi-disciplinary group?: Yes

Includes systematic review?: Yes

Grades quality of strength of evidence?: Yes

Grades quality of strength of recommendation?: Yes

Discloses funding source?: Yes

Discloses conflicts of interest?: Yes

Includes benefits/harms analysis with recommendations?: No

Strong Recommendation	Conditional Recommendation
The group is confident that the desirable effects of adherence to a recommendation outweigh the undesirable effects.	The group concludes that the desirable effects of adherence to a recommendation probably outweigh the undesirable effects but is not confident of this interpretation.